Table 2.

Characteristics of combination answer selections for Scenarios A-C.

	N	Overall % if no specialty difference	Rheum %	Neph %	∗p-value of specialty difference
Scenario A	122
Cyclophosphamide	77	∗	36.4	63.6	p=0.0114
+ IV/PO Steroid	71	92.2
+ Rituximab	26	∗	61.5	38.5	p=0.001
+ Plasmapheresis	14	19.5
+ Rituximab + Plasmapheresis	9	11.7
Rituximab without Cyclophosphamide	39	60
+ IV/PO Steroid	36	92.3
+ IV/PO Steroid + Plasmapheresis	6	15.4
IV/PO Steroid without Cyclophosphamide, Rituximab, or Plasmapheresis	6	∗	0	100	p<0.0001
Scenario B  My preferences would be different than that chosen in Scenario A	75	61.5
Cyclophosphamide	61	81.3
+ IV/PO Steroid	52	85.3
+ Rituximab	23	∗	65.2	34.8	p=0.0185
+ Plasmapheresis	40	65.6
+ Rituximab + Plasmapheresis	17	27.8
Rituximab without Cyclophosphamide	7	9.3
+ IV/PO Steroid	0	0
+ IV/PO Steroid + Plasmapheresis	7	100
Plasmapheresis without Cyclophosphamide or Rituximab	6	∗	0	100	p<0.0001
Other i	1	1.3
Scenario C  My preferences would be different than that chosen in Scenario A	72	∗	47.2	67.7	p=0.0232
Cyclophosphamide	45	63.4
+ IV/PO Steroid	40	88.9
+ Rituximab	16	35.6
+ Plasmapheresis	40	88.9
+ Rituximab + Plasmapheresis	13	32.5
Rituximab without Cyclophosphamide	13	18.3
+ IV/PO Steroid	12	92.3
+ IV/PO Steroid + Plasmapheresis	10	83.3
Plasmapheresis without Cyclophosphamide or Rituximab	11	13.4
Other ii	3	4.1

 ⁱOne subject chose ‘other' but did not describe treatment in free text.

 ⁱⁱOne subject chose ‘other' but did not describe treatment in free text; two did not select any option.